PSSD
A iatrogenic syndrome induced by antidepressant use
Est. Prevalence: Unknown– up to 52% of former users of antidepressants
What is PSSD?
PSSD, or Post-SSRI Sexual Dysfunction, is a syndrome consisting of a variety of symptoms that span multiple medical domains. While the name may allude to a purely genitourinary illness, the patient experience is typically something much more systemic than a simple sexual dysfunction. The most prevailing symptoms excluding a global sexual dysfunction include anhedonia, brain fog, visual disturbances, hypo/hyperhidrosis (sweating issues), memory loss, chronic fatigue, sleeping disturbances, and aphantasia (reduced mental imagery). You can use an all-encompassing interactive tool regarding PSSD symptoms below.
The exact prevalence of PSSD is yet to be determined, and attempts to identify the exact frequency have yielded vastly different results. For instance, a study hailing from Israel examining thousands of antidepressant users pinpointed a frequency of 1 in 216. Other studies have much higher estimates– with one estimating that over 50% of former antidepressant users experience PSSD to varying degrees of severity.
A general consensus among the medical community alluding to the true nature of the illness has yet to emerge, but there are several theories that circulate among the post-exposure community. The most prevailing theories include gut microbiome dysfunction, iatrogenic autoimmune dysautonomia with small fiber neuropathy, epigenetic and monoamine disturbances, among others. However, we at PEF are confident that all of these theories hold a certain level of truth. We believe that PSSD, like all other post-exposure syndromes, falls under the umbrella of an Infection-Associated Chronic Conditions and Illnesses (IACCI), as outlined by the world-renowned Mount Sinai Hospital in April 2026.
Nevertheless, progress towards universal awareness is occurring irrespective of a fully formed clinical picture. Multiple medical agencies such as the European Medical Agency (EMA) and Australia’s Therapeutic Goods Agency (TGA) have begun including warnings of persistent symptoms on antidepressant packaging. In addition, a notable sign of institutional recognition is that in October 2024, PSSD was added to SNOMED CT, an international set of clinical healthcare terminology used in electronic health records with the code SCTID 1340196008, meaning clinicians can now formally record a PSSD diagnosis.
Overall, the trajectory is encouraging — but formal recognition has not yet translated into clinical pathways, validated treatments, or adequate support for the hundreds of thousands of patients currently living with PSSD. PEF exists to bridge that gap: connecting patients with specialists, documenting interventions, increasing awareness through the PEF Project and building the evidence base that will eventually close the distance between awareness and answers.
PSSD: Symptoms
Diagnosis & Treatment
While there is no definitive test for PSSD such as a blood test or an antibody panel, there is an official diagnostic criteria outlined by post-exposure expert Dr. David Healy. The criteria was created by the means of thorough analysis of a published case series with the help of a panel of experts among a variety of disciplines. The guideline published by Healy lists two subtypes of PSSD: Classic Post-SSRI Sexual Dysfunction, and Post-SSRI Asexuality.
Classic PSSD can be induced by any serotonin-reuptake (SRI) medication. These include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), SRI tricyclic antidepressants, SRI antihistamines, tetracycline antibiotics such as doxycycline, and analgesics like tramadol. However, some anecdotal reports unrelated to Healy’s work mention PSSD induced from other classes of medications such as antipsychotics.
Diagnosis: Classic PSSD
The required criteria to be diagnosed with classic PSSD include:
Prior treatment with a serotonin reuptake inhibitor.
An enduring change in somatic (tactile) or erogenous (sexual) genital sensation after treatment stops.
No evidence of pre-drug sexual dysfunction that matches the current profile
No current medical conditions, medication, or substance use that could account for the symptoms.
Optional criteria outlined by Healy include:
Duration of ≥3 months after stopping treatment.
Enduring reduction or loss of sexual desire.
Enduring inability to orgasm or decreased sensation of pleasure during orgasm.
Enduring erectile dysfunction (males).
Decreased or loss of nocturnal erections (males)
Reduced ejaculatory force (males)
Genital pain
Reduced nipple sensitivity
Flaccid glans during erection (males)
Decreased vaginal lubrication (females).
Optional criteria apart from sexual and genitourinary symptoms include:
emotional numbing
depersonalization
cognitive impairment
other sensory problems involving skin, smell, taste or vision
Diagnosis: Post-SSRI Asexuality
Human studies have alluded that exposure to SRI medication in utero, or at early-age, result in sexual deficits in adulthood. This form of PSSD is known as Post-SSRI Asexuality. Since the onset ranges from the neonatal phase up until the onset of adolescence, sufferers of Post-SSRI Asexuality have no pre-drug baseline to assess their natural sexual functioning.
Post-SSRI Asexuality is diagnosed if the following criteria are met:
Clear evidence of maternal SRI intake in pregnancy or
Evidence of extended pre-teen SRI intake.
Lack of sexual interest in either the same sex or the opposite sex.
No experience of pleasure from masturbation or sexual activity ever.
Identification as asexual.
Treatment
Currently, there is no established protocol to treat or cure any form of PSSD. However, anecdotal data strongly supports the notion that recovery is possible. However, there are many who have that reported some sort of relief from PSSD.
Treatments for PSSD vary widely, and it is important to consult with a licensed medical professional before trialing anything. Nevertheless, some the most promising treatments include:
Cyproheptadine
Bupropion (Wellbutrin)
HCG Injections (for men only)
Others have seen relief from vastly different avenues such as homeopathic remedies, fecal microbial transplants, and even lithium.